Cho C W, Kwon C H D, Kim J M, Choi G-S, Joh J-W, Lee S-K
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Transplant Proc. 2017 Jun;49(5):1126-1128. doi: 10.1016/j.transproceed.2017.03.014.
Liver transplantation (LT) is an effective treatment for patients with end-stage liver disease caused by auto-immune hepatitis (AIH). However, diagnosis of AIH can be challenging for patients with end-stage liver disease at the time of transplantation. We classified patients into "probable" or "definite" AIH groups, using the diagnostic criteria of the International Autoimmune Hepatitis Group, and compared the clinical outcomes of AIH after LT in these 2 groups.
We performed a retrospective study of 18 patients who were diagnosed with AIH and underwent LT from March 2003 to March 2015 at a single institute. Of the 18 patients, 8 were diagnosed with definite AIH and 10 were diagnosed with probable AIH, according to the international scoring criteria. We evaluated the patient characteristics, recurrence rate, graft loss, and survival rates after LT.
The mean follow-up duration was 59.3 months. Age, sex, medical condition at transplantation, warm ischemic time, cold ischemic time, and Model for End-Stage Liver Disease score did not differ significantly between the 2 groups. No patient died after LT in either group, but 1 patient in the definite AIH group had graft failure. In Kaplan-Meier analysis, the 5-year recurrence rates of the definite and probable groups were 14.3% and 0%, respectively (P = .992).
The recurrence of definite AIH appeared to be higher than that of probable AIH. However, careful immunosuppressive therapy allowed the long-term survival of both definite and probable AIH patients after LT.
肝移植(LT)是自身免疫性肝炎(AIH)所致终末期肝病患者的有效治疗方法。然而,对于移植时处于终末期肝病的患者,AIH的诊断可能具有挑战性。我们采用国际自身免疫性肝炎小组的诊断标准,将患者分为“可能”或“确诊”AIH组,并比较这两组患者肝移植后AIH的临床结局。
我们对2003年3月至2015年3月在一家机构被诊断为AIH并接受肝移植的18例患者进行了一项回顾性研究。根据国际评分标准,18例患者中,8例被诊断为确诊AIH,10例被诊断为可能AIH。我们评估了患者特征、复发率、移植物丢失和肝移植后的生存率。
平均随访时间为59.3个月。两组患者的年龄、性别、移植时的病情、热缺血时间、冷缺血时间和终末期肝病模型评分无显著差异。两组均无患者在肝移植后死亡,但确诊AIH组有1例患者出现移植物功能衰竭。在Kaplan-Meier分析中,确诊组和可能组的5年复发率分别为14.3%和0%(P = 0.992)。
确诊AIH的复发似乎高于可能AIH。然而,谨慎的免疫抑制治疗使确诊和可能AIH患者在肝移植后均能长期存活。